Yael Weiss rare disease startup, Senti Bio cancer program win multimillion-dollar CIRM grants
SNTI Stock | USD 2.18 0.01 0.46% |
Under 54% of Senti Biosciences' investor base is interested to short. The analysis of the overall investor sentiment regarding Senti Biosciences suggests that many traders are impartial. Senti Biosciences' investing sentiment shows overall attitude of investors towards Senti Biosciences.
Senti |
Yael Weiss, CEO of Mahzi Therapeutics
Read at bizjournals.com
Senti Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Senti Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Senti Biosciences Fundamental Analysis
We analyze Senti Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Senti Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Senti Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Senti Biosciences is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Senti Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Senti Biosciences stock to make a market-neutral strategy. Peer analysis of Senti Biosciences could also be used in its relative valuation, which is a method of valuing Senti Biosciences by comparing valuation metrics with similar companies.
Peers
Senti Biosciences Related Equities
LIPO | Lipella Pharmaceuticals | 12.55 | ||||
FENC | Fennec Pharmaceuticals | 6.39 | ||||
RAPT | RAPT Therapeutics | 3.70 | ||||
TYRA | Tyra Biosciences | 2.21 | ||||
QNRX | Quoin Pharmaceuticals | 1.69 | ||||
MLYS | Mineralys Therapeutics, | 1.68 | ||||
FHTX | Foghorn Therapeutics | 0.77 | ||||
CING | Cingulate | 0.42 | ||||
XLO | Xilio Development | 1.12 | ||||
CNTB | Connect Biopharma | 2.00 | ||||
SABS | SAB Biotherapeutics | 3.19 | ||||
MNPR | Monopar Therapeutics | 3.48 | ||||
CVKD | Cadrenal Therapeutics, | 9.54 |
Complementary Tools for Senti Stock analysis
When running Senti Biosciences' price analysis, check to measure Senti Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senti Biosciences is operating at the current time. Most of Senti Biosciences' value examination focuses on studying past and present price action to predict the probability of Senti Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senti Biosciences' price. Additionally, you may evaluate how the addition of Senti Biosciences to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |